Catalyst Private Wealth’s Rapport Therapeutics RAPP Stock Holding History

Catalyst Private Wealth’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$417K	Hold	10,000	–	–	0.2%	56
2026 Q1	$313K	Hold	10,000	–	–	0.17%	60
2025 Q4	$303K	Hold	10,000	–	–	0.13%	65
2025 Q3	$297K	Hold	10,000	–	–	0.13%	67
2025 Q2	$114K	Hold	10,000	–	–	0.05%	78
2025 Q1	$100K	Buy	+10,000	New	+$130K	0.05%	77

Other funds holding RAPP

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Catalyst Private Wealth's RAPP Position: Q2 2026 in Review

Catalyst Private Wealth held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 10,000 shares worth $417K. The position accounts for 0.2% of the portfolio, ranked #56.

Catalyst Private Wealth first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. 24 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Catalyst Private Wealth held 10,000 shares of Rapport Therapeutics worth $417K as of Q2 2026.
Catalyst Private Wealth left its Rapport Therapeutics share count unchanged in Q2 2026.
Rapport Therapeutics made up 0.2% of Catalyst Private Wealth's portfolio in Q2 2026, its #56 holding.
Catalyst Private Wealth first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
24 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Catalyst Private Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.